- Home
- Test Categories
- Allergy Testing
- Autoimmune Diseases
- Blood and Blood Diseases
- Cancer Detection
- Diabetes
- DNA, Paternity and Genetic Testing
- Drug Screening
- Environmental Toxin Testing
- Female Specific Tests
- Fitness, Nutrition and Anti-Aging
- Gastrointestinal Diseases
- General Wellness
- Heart Health and Cholesterol
- Hormones and Metabolism
- Immunization Check
- Infectious Diseases
- Infertility Testing
- Kidney Diseases
- Liver Diseases
- Male Specific Tests
- Musculoskeletal Diseases
- Sexually Transmitted Diseases (STD's)
- Therapeutic Drug Monitoring
- Thyroid Diseases
- - STD Testing
- About STD Testing
- Chlamydia and Gonorrhea Test
- Cytomegalovirus (CMV) Antibodies, IgG
- Cytomegalovirus (CMV) Antibodies, IgM, Quantitative
- Epididymitis Screen
- Hepatitis A and B Immune Status Profile Test
- Hepatitis A and B Profile, Acute Diagnostic
- Hepatitis A and B Profile, Comprehensive
- Hepatitis A Antibody, IgM
- Hepatitis A Antibody, Total
- Hepatitis A Profile, Acute verses Chronic Differentiation
- Hepatitis B and C Profile Test (Comprehensive)
- Hepatitis B Core Antibody, IgG, IgM, Differentiation
- Hepatitis B Core Antibody, IgM
- Hepatitis B Core Antibody, Total
- Hepatitis B Patient Management Profile Test
- Hepatitis B Profile
- Hepatitis B Surface Antibody Test
- Hepatitis C Antibody Test
- Hepatitis C Virus (HCV), RNA PCR, Qualitative
- Hepatitis Panel, Acute
- Hepatitis Profile II (Diagnostic Follow-up)
- Herpes Simplex Virus (HSV) Type I and II IgG
- Herpes Simplex Virus (HSV) Type II IgG
- Herpes Simplex Virus (HSV), Type I and II IgM
- HIV-1 and HIV-2 Screen
- HIV-1 Antibodies Test
- HIV-1 DNA RT- PCR With HIV Antibodies , ICMA
- HIV-2 Antibodies
- Human Immunodeficiency Virus 1 (HIV-1) RNA (bDNA)
- Human Immunodeficiency Virus 2 (HIV-2), Qualitative, PCR
- Mycoplasma/Ureaplasma, Real-Time PCR
- Soluble Liver Antigen (SLA) IgG Antibody (Autoimmune Hepatitis)
- STD Recent Exposure Panel
- STD Urinary Tract Infection Panel
- Syphilis (RPR) Test
- Treponema pallidum Antibodies (TP-PA)
- Ultimate STD Panel
- Ultimate Viral STD Panel
- See All STD Tests
- - Blood Tests
- Allergy Testing
- Autoimmune Disease Testing
- Blood Disorder and Blood Disease Testing
- Cancer Detection Testing
- Diabetes Testing
- DNA, Paternity and Genetic Testing
- Drug Screening Testing
- Environmental Testing
- Female-Specific Testing
- Fitness, Nutrition and Anti-Aging Testing
- Gastrointestinal Disease Testing
- General Wellness Testing
- Heart Health and Cholesterol Testing
- Hormone Blood Tests
- Immunization Testing
- Infectious Disease Testing
- Infertility Testing
- Kidney Disease Testing
- Liver Function Tests
- Musculoskeletal Disorders Testing
- Prostate Testing
- Therapeutic Drug Monitoring Testing
- Thyroid Testing
- - All Tests
- Lab Locations
- Wishlist New!
- Why Online Lab Tests
- How it Works
- About Us
- FAQ
- Health Resources
Questions?
1.877.283.7882
1.877.283.7882
Private MD News
Home | News | Infectious DiseasesNew drug may give hope to those at risk for hepatitis C
Updated: 2009-12-04 21:46:57 CST Category: Infectious Diseases
by Brendan Missett
A new drug, which has been shown to prevent hepatitis C virus from replicating in a recent study of primates, may be of use to patients who have tested positive for the virus.
SPC3649, the new drug, targets an RNA molecule in the liver that hepatitis C uses to replicate, researchers told Health Day News.
The study, published in the December 3 online edition of Science, examined the levels of hepatitis C antibodies in the livers and bloodstreams of chimpanzees. Researchers found that by inhibiting the RNA molecule, the highest dose of SPC3649 reduced virus levels in the animals by 350-fold.
"It is a conceptually new approach," the study's lead author Robert Lanford of the Southwest Foundation for Biomedical Research told the news source. "Instead of directly targeting the virus, the drug targeted a liver-specific molecule necessary for replication."
Background information of the study revealed that about 170 million people are infected with hepatitis C worldwide, most commonly encountering the virus through contact with tainted blood.
According to the Centers for Disease Control and Prevention, between 70 percent and 80 percent of individuals with the virus initially have no symptoms, however more than 60 percent eventually develop chronic liver disease.
Related Articles from Private MD:
-
Health officials caution about reports of drop in H1N1 activity
-
Some Americans shun H1N1 vaccine, despite successful testing
-
Study: Better flu testing needed for patients with dementia
-
Infectious disease research fund may promote lab testing
-
Lack of H1N1 vaccine may bring about more lab tests
Subscribe to Private MD Health News RSS Feed: 
News Categories:
Advanced Lipid Treatment I Allergy Testing Anemia and RBC disorders Autoimmune Diseases Bariatric Lab Testing Blood and Blood Diseases Breast Cancer Detection and Tumor Markers Celiac Disease Testing Chlamydia Coagulation and blood clotting disorders Colon Diabetes DNA, Paternity and Genetic testing Drug Screening Environmental Toxin Testing Female Specific Tests Gastrointestinal Diseases General Health General Wellness Heart Health and Cholesterol Herpes HIV HIV monitoring/Treatment/Testing/Post Diagnos Hormones and Metabolism Infectious Diseases Infertility Testing-Male Infertitlity Hormone Testing Kidney Diseases Leukemia and WBC disorders Liver Liver Diseases Lyme Disease Male Specific Tests Menopause/Peri-Menopausal Diagnosis Organ Specific Testing Ovarian Prostate Sexually Transmitted Diseases Thyroid Diseases Vitamin D Deficiency-Diagnosis and Treatment
Visit the Health News Archive: Click Here
Questions about online blood testing or how to order a lab test? Click here to get started or call us toll-free at 1.877.283.7882. Our certified professionals are ready to assist you.
